- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00274313
Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
January 12, 2009 updated by: Parion Sciences
A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis
The purpose of this study is to evaluate the safety and tolerability of a new inhaled sodium-channel blocker called 552-02 in teens and adults with cystic fibrosis.
552-02 will be inhaled once a day for 14 days using a nebulizer.
A small subgroup of patients will donate blood samples for pharmacokinetic analysis to see how 552-02 is absorbed into the blood and eliminated after 14 days of treatment.
Study Overview
Study Type
Interventional
Enrollment
40
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92161
- University of California at San Diego
-
San Francisco, California, United States, 94143-0359
- University of California at San Francisco Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80218
- The Children's Hospital
-
-
Florida
-
Orlando, Florida, United States, 32806-1101
- Nemours Children's Clinic
-
Tampa, Florida, United States, 33606
- University of South Florida
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Children's Memorial Hospital
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-5190
- University of Nebraska Medical Center
-
-
New Jersey
-
Morristown, New Jersey, United States, 07962
- Morristown Memorial Hospital
-
-
New York
-
Syracuse, New York, United States, 13210
- State University of New York Upstate
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19104-4399
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female patients aged > 14 years.
- Patients who are diagnosed with cystic fibrosis.
- Patients who have a FEV1 ≥ 50% predicted (post-bronchodilator) at screening.
- Patients who are able to perform reproducible spirometry according to ATS guidelines.
- Patients who have an oxygen saturation of ≥ 92% on room air as determined by pulse oximetry at screening.
Exclusion Criteria:
- Patients who have a FEV1 change ≥ 15% after bronchodilator use at screening.
- Patients who have unstable lung disease as defined by the requirement for intravenous antibiotics during the four weeks prior to screening, a change in medical regimen within 14 days prior to administration of the first dose of study drug or during the 14 day treatment period, a FEV1 ≥ 15% below recent (within six months) clinical measurements, or significant new findings on chest radiograph (pneumothorax, lobar/segmental collapse) that are not considered a part of the usual, chronic progression of cystic fibrosis lung disease.
- Patients on angiotensin converting enzyme (ACE) inhibitors.
- Patients with renal insufficiency as evidenced by hyperkalemia (blood potassium levels greater than 5.5 mEq/L) or serum creatinine > 2.0 mg/dL.
- Patients who have a history of drug allergies to any medicine chemically related to the study drug (e.g. amiloride, Moduretic, Midamor; triamterene).
- Patients who are pregnant, have a positive pregnancy test, or are nursing.
- Patients who have had a lung transplant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety assessments
|
Blood and urine laboratory tests
|
Pulmonary function tests
|
Electrocardiograms
|
Vital signs and pulse oximetry
|
Secondary Outcome Measures
Outcome Measure |
---|
Plasma pharmacokinetics on Day 14 of the study.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Study Completion
August 1, 2006
Study Registration Dates
First Submitted
January 6, 2006
First Submitted That Met QC Criteria
January 6, 2006
First Posted (Estimate)
January 10, 2006
Study Record Updates
Last Update Posted (Estimate)
January 14, 2009
Last Update Submitted That Met QC Criteria
January 12, 2009
Last Verified
January 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Parion 552-203
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
-
University Hospital, BordeauxCompleted
Clinical Trials on 552-02
-
Parion SciencesCompletedXerostomia | Dry Mouth Associated With Sjogren's SyndromeUnited States
-
AbbVieRecruitingAlzheimer's Disease (AD)United States, Japan, New Zealand, Australia, Spain, Germany, United Kingdom
-
Parion SciencesCompletedSjogren's Syndrome | XerostomiaUnited States
-
AbbVieCompleted
-
AbbVieRecruitingHealthy VolunteerUnited States
-
Zhongmou TherapeuticsNot yet recruitingRetinitis PigmentosaChina
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Tceleron Therapeutics, Inc.TerminatedMetastatic Castration-resistant Prostate CancerUnited States
-
Amniotics ABCompleted
-
Attralus, Inc.Novotech (Australia) Pty LimitedRecruitingAmyloidosis; SystemicUnited States, Australia